JAK Inhibition in Food Allergy
This study will assess the role for an oral targeted medication, abrocitinib, as a new
treatment option for food allergy patients that would avoid injections. Abrocitinib, which
has successfully completed phase three trials for atopic dermatitis, could serve as a si...
Age: 18 - 50 years
Gender: All
Systems Biology of Early Atopy
The goal of this study is to establish a birth cohort that collects prenatal and early life
biosamples and environmental samples and rigorously phenotypes young children for food
allergy and Atopic Dermatitis (AD) to identify prenatal and early life markers of high ...
Age: 0 years - 66+
Gender: All
A Registry for Patients With Food Allergy
The FARE Patient Registry will serve as a prospective, observational food allergy reporting system that stores detailed health and other basic information about patients' real-world experiences with food allergies, to encourage open sharing of de-identified data and par...
Age: Birth - 66+
Gender: All
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
The purpose of the study is to determine if the combination of niraparib with Abiraterone
Acetate (AA) plus prednisone compared with AA plus prednisone in participants with
deleterious germline or somatic Homologous Recombination Repair (HRR) gene-mutated Metastatic...
Age: 18 years - 66+
Gender: Male
Diagnostic Accuracy and Safety of DBV1605 for the Diagnosis of Non-IgE Mediated Cow's Milk Allergy in Children
Study to assess the diagnostic accuracy (sensitivity, specificity, positive and negative predictive value) of DBV1605 for the diagnosis of non-Immunoglobulin E (IgE) mediated cow's milk allergy (CMA) in children with symptoms suggestive of non-IgE mediated CMA.
Age: Birth - 24 months
Gender: All
Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children
Open-label, follow-up study for subjects who completed the EPITOPE study.
Age: 2 - 5 years
Gender: All
Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008)
The purpose of this study is to assess AR101's safety, tolerability and efficacy over an
extended dosing period.
Age: 1 year - 55 years
Gender: All
PALISADE Follow-on Study (ARC004)
The purpose of this study is to demonstrate the safety, tolerability, and efficacy of AR101 through characterized oral desensitization immunotherapy (CODIT) in peanut-allergic children and adults who have completed the ARC003 study.
Age: 4 - 55 years
Gender: All
HAL-MPE1 Safety and Tolerability Study
The aim of this study is to confirm safety and tolerability of incremental doses of HAL-MPE1 subcutaneous immunotherapy (SCIT) in peanut allergic adults, and subsequently assess the safety and tolerability in adolescents and children with peanut allergy.
Age: 5 - 50 years
Gender: All